Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.45 |
| ▸ | FEN1 | P39748 | 5/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25581911 | 0.93 | KIF11 (0.49) | AKR1C3AKR1C2APPALOX5APKIF11 | |
| SCHEMBL10064833 | 0.87 | AKR1C3 (0.46) | AKR1C3AKR1C2KIF11MAOBPRMT3 | |
| SCHEMBL25094071 | 0.82 | KIF11 (0.60) | KIF11MAOB | |
| SCHEMBL22421796 | 0.82 | AKR1C3 (0.50) | AKR1C3AKR1C2APPALOX5APFEN1 | |
| SCHEMBL11989284 | 0.81 | APP (0.51) | AKR1C3AKR1C2APPALOX5AP | |
| SCHEMBL12050566 | 0.80 | SCD (0.49) | AKR1C3AKR1C2KIF11 | |
| SCHEMBL5121382 | 0.79 | APP (0.57) | AKR1C3AKR1C2APPALOX5APFEN1 | |
| SCHEMBL20557329 | 0.79 | TSHR (0.56) | AKR1C3AKR1C2APPALOX5APFEN1 | |
| SCHEMBL2573330 | 0.79 | TSHR (0.56) | AKR1C3AKR1C2ALOX5APFEN1MAOB | |
| SCHEMBL24721249 | 0.78 | AKR1C3 (0.56) | AKR1C3AKR1C2APPALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, IL2, JAK3 | AKR1C3 4455/4885AKR1C2 4167/4885APP 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.